These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

880 related items for PubMed ID: 19272537

  • 1. Neuromuscular transmission: new concepts and agents.
    de Boer HD.
    J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
    [Abstract] [Full Text] [Related]

  • 2. Preclinical pharmacology of sugammadex.
    Bom A, Hope F, Rutherford S, Thomson K.
    J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
    [Abstract] [Full Text] [Related]

  • 3. Clinical implications of new neuromuscular concepts and agents: so long, neostigmine! So long, sux!
    Lee C, Katz RL.
    J Crit Care; 2009 Mar; 24(1):43-9. PubMed ID: 19272538
    [Abstract] [Full Text] [Related]

  • 4. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
    de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M.
    Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
    [Abstract] [Full Text] [Related]

  • 5. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
    Ren WH, Jahr JS.
    Am J Ther; 2009 Aug; 16(4):295-9. PubMed ID: 19535969
    [Abstract] [Full Text] [Related]

  • 6. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gómez JA.
    Anesth Analg; 2010 Jan 01; 110(1):64-73. PubMed ID: 19713265
    [Abstract] [Full Text] [Related]

  • 7. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A, Ho J, Wong J, Yin L, Chung F.
    Anesth Analg; 2010 Apr 01; 110(4):1239. PubMed ID: 20357160
    [Abstract] [Full Text] [Related]

  • 8. A novel approach to reversal of neuromuscular blockade.
    Della Rocca G, Pompei L.
    Minerva Anestesiol; 2009 May 01; 75(5):349-51. PubMed ID: 19412157
    [Abstract] [Full Text] [Related]

  • 9. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.
    de Boer HD, van Esmond J, Booij LH, Driessen JJ.
    Paediatr Anaesth; 2009 Dec 01; 19(12):1226-8. PubMed ID: 19863737
    [Abstract] [Full Text] [Related]

  • 10. Sugammadex: the first selective binding reversal agent for neuromuscular block.
    Kovac AL.
    J Clin Anesth; 2009 Sep 01; 21(6):444-53. PubMed ID: 19833281
    [Abstract] [Full Text] [Related]

  • 11. Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.
    Hogg RM, Mirakhur RK.
    Expert Rev Neurother; 2009 May 01; 9(5):599-608. PubMed ID: 19402771
    [Abstract] [Full Text] [Related]

  • 12. Sugammadex in clinical practice.
    Mirakhur RK.
    Anaesthesia; 2009 Mar 01; 64 Suppl 1():45-54. PubMed ID: 19222431
    [Abstract] [Full Text] [Related]

  • 13. Clinical implications of sugammadex.
    Caldwell JE, Miller RD.
    Anaesthesia; 2009 Mar 01; 64 Suppl 1():66-72. PubMed ID: 19222433
    [Abstract] [Full Text] [Related]

  • 14. Sugammadex: another milestone in clinical neuromuscular pharmacology.
    Naguib M.
    Anesth Analg; 2007 Mar 01; 104(3):575-81. PubMed ID: 17312211
    [Abstract] [Full Text] [Related]

  • 15. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
    Duvaldestin P, Kuizenga K, Saldien V, Claudius C, Servin F, Klein J, Debaene B, Heeringa M.
    Anesth Analg; 2010 Jan 01; 110(1):74-82. PubMed ID: 19933538
    [Abstract] [Full Text] [Related]

  • 16. Sugammadex: a selective relaxant-binding agent providing rapid reversal.
    Rex C, Bergner UA, Pühringer FK.
    Curr Opin Anaesthesiol; 2010 Aug 01; 23(4):461-5. PubMed ID: 20489603
    [Abstract] [Full Text] [Related]

  • 17. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
    Sacan O, White PF, Tufanogullari B, Klein K.
    Anesth Analg; 2007 Mar 01; 104(3):569-74. PubMed ID: 17312210
    [Abstract] [Full Text] [Related]

  • 18. The use of sugammadex in a patient with myasthenia gravis.
    Unterbuchner C, Fink H, Blobner M.
    Anaesthesia; 2010 Mar 01; 65(3):302-5. PubMed ID: 20105151
    [Abstract] [Full Text] [Related]

  • 19. Reversal of profound rocuronium or vecuronium-induced neuromuscular block with sugammadex in isoflurane-anaesthetised dogs.
    Mosing M, Auer U, West E, Jones RS, Hunter JM.
    Vet J; 2012 Jun 01; 192(3):467-71. PubMed ID: 22030475
    [Abstract] [Full Text] [Related]

  • 20. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
    Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, Eikermann M, Khuenl-Brady KS.
    Anesthesiology; 2008 Aug 01; 109(2):188-97. PubMed ID: 18648227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.